JP2013519636A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519636A5
JP2013519636A5 JP2012552352A JP2012552352A JP2013519636A5 JP 2013519636 A5 JP2013519636 A5 JP 2013519636A5 JP 2012552352 A JP2012552352 A JP 2012552352A JP 2012552352 A JP2012552352 A JP 2012552352A JP 2013519636 A5 JP2013519636 A5 JP 2013519636A5
Authority
JP
Japan
Prior art keywords
fviii
domain
linked
psa
fviii variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012552352A
Other languages
English (en)
Japanese (ja)
Other versions
JP5933457B2 (ja
JP2013519636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/051723 external-priority patent/WO2011101267A1/en
Publication of JP2013519636A publication Critical patent/JP2013519636A/ja
Publication of JP2013519636A5 publication Critical patent/JP2013519636A5/ja
Application granted granted Critical
Publication of JP5933457B2 publication Critical patent/JP5933457B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012552352A 2010-02-16 2011-02-07 コンジュゲートｆｖｉｉｉバリアント Expired - Fee Related JP5933457B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153718 2010-02-16
EP10153718.1 2010-02-16
US30560810P 2010-02-18 2010-02-18
US61/305,608 2010-02-18
PCT/EP2011/051723 WO2011101267A1 (en) 2010-02-16 2011-02-07 Conjugated fviii variants

Publications (3)

Publication Number Publication Date
JP2013519636A JP2013519636A (ja) 2013-05-30
JP2013519636A5 true JP2013519636A5 (enExample) 2014-03-27
JP5933457B2 JP5933457B2 (ja) 2016-06-08

Family

ID=42173354

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012553254A Expired - Fee Related JP5914363B2 (ja) 2010-02-16 2011-02-02 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
JP2012552352A Expired - Fee Related JP5933457B2 (ja) 2010-02-16 2011-02-07 コンジュゲートｆｖｉｉｉバリアント

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012553254A Expired - Fee Related JP5914363B2 (ja) 2010-02-16 2011-02-02 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子

Country Status (5)

Country Link
US (4) US20130040888A1 (enExample)
EP (2) EP2536753B1 (enExample)
JP (2) JP5914363B2 (enExample)
CN (3) CN105524164A (enExample)
WO (2) WO2011101242A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
HRP20191920T1 (hr) * 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
HK1200695A1 (en) * 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
ES2770501T3 (es) * 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
JP2015533152A (ja) 2012-10-15 2015-11-19 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 第ｖｉｉ因子コンジュゲート
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
ES2819217T3 (es) * 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
CA2927756A1 (en) 2013-10-15 2015-04-23 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
AR101060A1 (es) * 2014-02-12 2016-11-23 Novo Nordisk As Conjugados de fviii
AR099328A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados de factor vii
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
CA2942770A1 (en) * 2014-03-23 2015-10-01 Advantech Bioscience Farmaceutica Ltda. Enhancement of recombinant protein expression with copper
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
EP3207128B1 (en) 2014-10-17 2022-07-27 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
IL290457B2 (en) * 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
KR102219859B1 (ko) * 2016-06-24 2021-02-25 재단법인 목암생명과학연구소 재조합 단쇄 fviii 및 그 화학 접합물
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3642225A1 (en) * 2017-06-23 2020-04-29 Baxalta Incorporated Purification of factor viii subspecies
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN117467019A (zh) 2018-05-18 2024-01-30 郑州晟斯生物科技有限公司 改进的fviii融合蛋白及其应用
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
MX2022002337A (es) 2019-08-27 2022-06-08 Tonix Pharma Ltd Polipéptidos de tff2 modificados.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021094344A1 (en) 2019-11-11 2021-05-20 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
AU2645588A (en) * 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE69936409T2 (de) 1998-04-28 2008-04-17 Laboratoires Serono S.A., Coinsins Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP1446438A2 (en) * 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US8048408B2 (en) 2002-01-16 2011-11-01 Biocompatibles Uk Limited Polymer conjugates
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
US8217154B2 (en) 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
JP5235657B2 (ja) 2005-03-24 2013-07-10 バイオジェネリックス ゲーエムベーハー 原核生物における可溶性活性真核生物グリコシルトランスフェラーゼの発現
US20080227691A1 (en) * 2005-04-01 2008-09-18 Novo Nordisk Health Care Ag Blood Coagulation FVIII Analogues
BRPI0611570A2 (pt) 2005-06-15 2011-02-22 Novo Nordisk Healthcare Ag métodos para fixar covalentemente peg a um polipeptìdeo e para modificar propriedades farmacológicas de hormÈnio de crescimento, composto e sais, pró-drogas ou solvatos farmaceuticamente aceitáveis do mesmo, hormÈnio de crescimento humano, composição farmacêutica, método para tratamento de doença e, uso de um composto
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2007087711A1 (en) 2006-01-31 2007-08-09 National Research Council Of Canada Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2007126808A1 (en) 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
EP2162535A4 (en) 2007-06-04 2011-02-23 Novo Nordisk As O-linked glycosylation using N-acetylglucosamine transferases
US8460909B2 (en) 2007-06-15 2013-06-11 National Research Council Of Canada Engineered versions of polysialyltransferases with enhanced enzymatic properties
AU2008323768A1 (en) 2007-11-09 2009-05-14 Baxter Healthcare S.A. Modified recombinant Factor VIII and von Willebrand Factor and methods of use
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
US20130189239A1 (en) * 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
PT2349342T (pt) 2008-10-17 2018-10-26 Baxalta Inc Factores sanguíneos modificados que compreendem um baixo grau de polímero solúvel na água
US20110306551A1 (en) 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
ES2427627T3 (es) * 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
WO2011101284A1 (en) * 2010-02-16 2011-08-25 Novo Nordisk A/S Factor viii fusion protein

Similar Documents

Publication Publication Date Title
JP2013519697A5 (enExample)
JP2010215657A5 (enExample)
IN2014DN00101A (enExample)
EA201491441A1 (ru) Композиции конъюгата xten и способы их получения
JP2012255007A5 (enExample)
JP2011515499A5 (enExample)
JP2015536943A5 (enExample)
CO6450686A2 (es) Compuesto biocompatible y su uso
JP2015519313A5 (enExample)
JP2012508172A5 (enExample)
EA201170039A1 (ru) Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения
JP2014515039A5 (enExample)
BR112012012210B8 (pt) conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
WO2010122385A8 (fr) Formulation a action rapide d'insuline
HK1205156A1 (en) Cyclodextrin-based polymers for therapeutic delivery
SG194175A1 (en) Polymer conjugated prostaglandin analogues
PH12013501893A1 (en) Blends of a polylactic acid and a water soluble polymer
IN2012DN00407A (enExample)
UA101497C2 (ru) Конъюгаты фактора ix с увеличенным временем полужизни
MX392770B (es) Composición farmacéutica de estabilidad mejorada.
MX2010009154A (es) Moleculas conjugadas del factor viii.
JP2014058562A5 (enExample)
WO2012017288A3 (en) Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
AU2016219615A1 (en) Pharmaceutical compositions comprising modified fucans for use in the treatment of fibrous adhesions and other disorders
WO2018056937A3 (en) Nanofibrous adhesion barrier